BMO Capital analyst Do Kim raised his price target on Alnylam to $126 and kept his Outperofrm rating after the company's presented Givosiran phase 3 data at EASL, also raising his probability of success estimate for the program to 100% from 70%. Based on the "clear, robust efficacy and reasonable safety for an ultra-rare disease with limited treatment options", the analyst believes that Givosiran's risk/benefit profile supports approval, adding that the already granted "breakthrough" designation for the program by the FDA and PRIME designation by the EMA should further facilitate approval. Do Kim expects the approval to take place in early 2020 after U.S. and E.U. regulators complete their rolling submissions in mid-2019.